Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (120)	11/11/2003 5:37:20 PM
From: Biomaven	Respond to of 411

My memory of Adentri is that the original formulation was IV only, and Biogen then went forward with a new molecule in both IV and oral forms. They never gave much information on the program or the switch, and at some point (earlier this year I think) did say they were going to outlicense it. Maybe they've now changed their mind(s) in the context of the merger (or perhaps because of the results)? A diuretic that didn't impact the kidneys or potassium levels would be a big player in the heart failure market. From the date of the original license I assume that CVTX can't expect much in the way of royalties though. Mid/upper single digits maybe? Peter